Demographic characteristics of patients enrolled in the phase 1 study plus the expansion cohort of patients with peripheral T-cell lymphoma
| Characteristic . | Data (N = 31) . |
|---|---|
| Age, median (range), y | 57 (23-79) |
| Sex, n (%) | |
| Male | 19 (61) |
| Female | 12 (39) |
| Ethnicity, n (%) | |
| White, non-Hispanic | 19 (61) |
| White, Hispanic | 6 (20) |
| Black, non-Hispanic | 1 (3) |
| Black, Hispanic | 4 (13) |
| Asian or Pacific Islander | 1 (3) |
| Lymphoma subtype, n (%) | |
| Hodgkin lymphoma | 12 (39) |
| Diffuse large B-cell lymphoma* | 6 (20) |
| Follicular lymphoma | 2 (6) |
| T-cell lymphoma | 11 (35) |
| Angioimmunoblastic T-cell lymphoma | 3 (10) |
| Adult T-cell leukemia/lymphoma | 2 (6) |
| Peripheral T-cell lymphoma-NOS (cutaneous) | 1 (3) |
| Anaplastic large cell lymphoma, cutaneous | 1 (3) |
| Cutaneous T-cell lymphoma | 1 (3) |
| Enteropathy-associated T-cell lymphoma | 1 (3) |
| Extranodal natural killer/T-cell lymphoma | 1 (3) |
| T-cell lymphoblastic lymphoma | 1 (3) |
| Median number of prior therapies | 6 (1-15) |
| Prior regimens (at least 1 cycle), n (%) | |
| Hodgkin lymphoma (n = 12) | |
| ABVD-like, BEACOPP | 12 (39) |
| Platinum-based (ICE, ESHAP) | 12 (39) |
| Bv-based (Bv, Bv+B, Bv+AVD) | 12 (39) |
| Other alkylator-based (COPP, MOPP, B) | 11 (35) |
| Lenalidomide | 8 (26) |
| Gem-based (gem or GND) | 7 (23) |
| Experimental drug† | 7 (23) |
| Other therapy‡ | 6 (20) |
| B-cell lymphoma (n = 8) | |
| Anthracycline-based (R-CHOP, R-EPOCH) | 7 (23) |
| Platinum-based (R-ICE, R-DICE) | 6 (20) |
| Nonanthracycline-based (R-CVP, R-FND, R-B, R-B-bortezomib, R-F) | 4 (13) |
| Single agent anti-CD20 antibody (rituximab, ublituximab) | 4 (13) |
| Idelalisib + rituximab | 2 (6) |
| Experimental drug or other therapy§ | 5 (16) |
| T-cell lymphoma (n = 11) | |
| Anthracycline-based (CHOP, CHOEP, EPOCH±bortezomib) | 8 (26) |
| Gem-based (gem, p-gemox, gem+liposomal cytarabine) | 4 (13) |
| HDAC inhibitor (vorinostat, ROMI) | 3 (10) |
| Bv | 2 (6) |
| Pralatrexate | 1 (3) |
| Experimental drug or other therapy, n (%)‖ | 6 (20) |
| Prior ASCT, n (%) | 16 (52) |
| Prior alloSCT, n (%) | 5 (16) |
| Radiotherapy/radioimmunotherapy, n (%) | 10 (32) |
| Characteristic . | Data (N = 31) . |
|---|---|
| Age, median (range), y | 57 (23-79) |
| Sex, n (%) | |
| Male | 19 (61) |
| Female | 12 (39) |
| Ethnicity, n (%) | |
| White, non-Hispanic | 19 (61) |
| White, Hispanic | 6 (20) |
| Black, non-Hispanic | 1 (3) |
| Black, Hispanic | 4 (13) |
| Asian or Pacific Islander | 1 (3) |
| Lymphoma subtype, n (%) | |
| Hodgkin lymphoma | 12 (39) |
| Diffuse large B-cell lymphoma* | 6 (20) |
| Follicular lymphoma | 2 (6) |
| T-cell lymphoma | 11 (35) |
| Angioimmunoblastic T-cell lymphoma | 3 (10) |
| Adult T-cell leukemia/lymphoma | 2 (6) |
| Peripheral T-cell lymphoma-NOS (cutaneous) | 1 (3) |
| Anaplastic large cell lymphoma, cutaneous | 1 (3) |
| Cutaneous T-cell lymphoma | 1 (3) |
| Enteropathy-associated T-cell lymphoma | 1 (3) |
| Extranodal natural killer/T-cell lymphoma | 1 (3) |
| T-cell lymphoblastic lymphoma | 1 (3) |
| Median number of prior therapies | 6 (1-15) |
| Prior regimens (at least 1 cycle), n (%) | |
| Hodgkin lymphoma (n = 12) | |
| ABVD-like, BEACOPP | 12 (39) |
| Platinum-based (ICE, ESHAP) | 12 (39) |
| Bv-based (Bv, Bv+B, Bv+AVD) | 12 (39) |
| Other alkylator-based (COPP, MOPP, B) | 11 (35) |
| Lenalidomide | 8 (26) |
| Gem-based (gem or GND) | 7 (23) |
| Experimental drug† | 7 (23) |
| Other therapy‡ | 6 (20) |
| B-cell lymphoma (n = 8) | |
| Anthracycline-based (R-CHOP, R-EPOCH) | 7 (23) |
| Platinum-based (R-ICE, R-DICE) | 6 (20) |
| Nonanthracycline-based (R-CVP, R-FND, R-B, R-B-bortezomib, R-F) | 4 (13) |
| Single agent anti-CD20 antibody (rituximab, ublituximab) | 4 (13) |
| Idelalisib + rituximab | 2 (6) |
| Experimental drug or other therapy§ | 5 (16) |
| T-cell lymphoma (n = 11) | |
| Anthracycline-based (CHOP, CHOEP, EPOCH±bortezomib) | 8 (26) |
| Gem-based (gem, p-gemox, gem+liposomal cytarabine) | 4 (13) |
| HDAC inhibitor (vorinostat, ROMI) | 3 (10) |
| Bv | 2 (6) |
| Pralatrexate | 1 (3) |
| Experimental drug or other therapy, n (%)‖ | 6 (20) |
| Prior ASCT, n (%) | 16 (52) |
| Prior alloSCT, n (%) | 5 (16) |
| Radiotherapy/radioimmunotherapy, n (%) | 10 (32) |
A(B)VD, Adriamycin, bleomycin, vinblastine, dacarbazine; B bendamustine; BAC, bendamustine, cytarabine; BEACOPP, bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; Bv, brentuximab vedotin; COPP, cyclophosphamide, vincristine, procarbazine, prednisone/Adriamycin; CVP, cyclophosphamide, vincristin, prednisone; (D)ICE, (dexamethasone) ifosphamide, carboplatin, etoposide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin; FND, fludarabine, mitoxanthrone, dexamethasone; Gem, gemcitabine; gemox, gemcitabine+oxaliplatin; GND, gemcitabine, navelbine, liposomal doxorubicin; IVAC, etoposide, ifosfamide, cytarabine, methotrexate; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; (R)-CHO(E)P, rituximab, cyclophosphamide, doxorubicin, vincristine (etoposide) prednisone; (p)GemOx, (peg-asparaginase) gemcitabine, oxaliplatin; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, etoposide.
3 nodal, 2 transformed from follicular lymphoma, 1 cutaneous.
ACY1215, umbralisib, PI3K inhibitor+JAK inhibitor, pralatrexate+ROMI, vorinostat+niacinamide, Nedd8-activating enzyme inhibitor MLN4924, CUDC907, belinostat, CPI-0610, SB743921, MDX-060.
EPOCH, IVAC, vinblastine+bleomycin+methotrexate, vinblastine, pembrolizumab (compassionate use), EBV-specific cytotoxic T-lymphocytes, alternative medicine.
Anti-CD37, vorinostat-niacinamide±etoposide, ibrutinib, umbralisib, pralatrexate, brentuximab vedotin, R-lenalidomide.
Pralatrexate+ROMI, bortezomib, Nelarabine, mogamulizumab, bexarotene, photopheresis±interferon, total skin electron beam therapy, pembrolizumab, bendamustine, ICE, SMILE, BAC.